Table of Content

1 INTRODUCTION
1.1 Study Assumptions
1.2 Scope of the Study


2 RESEARCH METHODOLOGY


3 EXECUTIVE SUMMARY


4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Rising Incidence of Neurological Diseases
4.2.2 Increasing Research and Development Activities
4.2.3 Growth in the Pharmaceutical and Biotechnology Industries
4.3 Market Restraints
4.3.1 High Cost Associated with the Production of Antibodies
4.4 Porter’s Five Force Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry


5 MARKET SEGMENTATION
5.1 By Product Type
5.1.1 Consumables
5.1.2 Instruments
5.2 By Technology
5.2.1 Immunoassays/Immunochemistry
5.2.2 Molecular Diagnostics
5.2.3 Others
5.3 By End User
5.3.1 Academic and Research Institutes
5.3.2 Pharmaceutical and Biotechnology Companies
5.3.3 Others
5.4 Geography
5.4.1 North America
5.4.1.1 United States
5.4.1.2 Canada
5.4.1.3 Mexico
5.4.2 Europe
5.4.2.1 Germany
5.4.2.2 United Kingdom
5.4.2.3 France
5.4.2.4 Italy
5.4.2.5 Spain
5.4.2.6 Rest of Europe
5.4.3 Asia-Pacific
5.4.3.1 China
5.4.3.2 Japan
5.4.3.3 India
5.4.3.4 Australia
5.4.3.5 South Korea
5.4.3.6 Rest of Asia-Pacific
5.4.4 Middle-East and Africa
5.4.4.1 GCC
5.4.4.2 South Africa
5.4.4.3 Rest of Middle-East and Africa
5.4.5 South America
5.4.5.1 Brazil
5.4.5.2 Argentina
5.4.5.3 Rest of South America


6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Thermo Fisher Scientific
6.1.2 Bio-Rad Laboratories, Inc
6.1.3 Merck & Co., Inc (Merck KGaA)
6.1.4 F. Hoffmann-La Roche
6.1.5 Cell Signaling Technology, Inc
6.1.6 BioLegend, Inc
6.1.7 Abcam Plc
6.1.8 Rockland Immunochemicals, Inc
6.1.9 GenScript
6.1.10 Santa Cruz Biotechnology, Inc


7 MARKET OPPORTUNITIES AND FUTURE TRENDS